Amylyx Pharmaceuticals, Inc. (AMLX) vs Arcutis Biotherapeutics, Inc. (ARQT)

A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Arcutis Biotherapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Amylyx Pharmaceuticals, Inc. logo
AMLX
Amylyx Pharmaceuticals, Inc.
$3.01B
$27.08HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Arcutis Biotherapeutics, Inc. logo
ARQT
Arcutis Biotherapeutics, Inc.
$3.04B
$24.34HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT

Total return — AMLX vs ARQT

growth of $100 · dividends reinvested · last 5y
AMLX +53.7% (+9.0%/yr)ARQT +27.7% (+5.0%/yr)AMLX compounded faster over this window
050100150200Start $1002023202420252026$154$128
AMLX ARQT

AMLX vs ARQT: by the numbers

  • •ARQT is the larger company ($3.04B vs $3.01B market cap).
  • •ARQT is profitable (6.15% net margin) while AMLX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricAMLXARQT
P/E ratioN/A116.74
Forward P/EN/A48.96
P/S ratioN/A6.56
P/B ratio12.5913.80
EV / EBITDAN/A83.99
FCF yieldN/A1.29%

Profitability

MetricAMLXARQT
Gross margin0.00%91.14%
Operating margin0.00%-3.25%
Net margin0.00%6.15%
ROE-63.59%12.93%
ROIC-66.60%9.95%

Growth (annualized)

MetricAMLXARQT
Total return CAGR (5Y)N/A-0.28%

Frequently asked

Is AMLX or ARQT more profitable?
ARQT runs the higher net margin — AMLX at 0.00% versus ARQT at 6.15%.

Go deeper

Full AMLX analysisFull ARQT analysisInteractive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratioAmylyx Pharmaceuticals ROEArcutis Biotherapeutics ROEAmylyx Pharmaceuticals operating marginArcutis Biotherapeutics operating marginAmylyx Pharmaceuticals revenue growthArcutis Biotherapeutics revenue growthAmylyx Pharmaceuticals free cash flowArcutis Biotherapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.